180 related articles for article (PubMed ID: 36531612)
1. Cell specific regulation of NaV1.7 activity and trafficking in rat nodose ganglia neurons.
Loya-López SI; Duran P; Ran D; Calderon-Rivera A; Gomez K; Moutal A; Khanna R
Neurobiol Pain; 2022; 12():100109. PubMed ID: 36531612
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain.
François-Moutal L; Dustrude ET; Wang Y; Brustovetsky T; Dorame A; Ju W; Moutal A; Perez-Miller S; Brustovetsky N; Gokhale V; Khanna M; Khanna R
Pain; 2018 Oct; 159(10):2115-2127. PubMed ID: 29847471
[TBL] [Abstract][Full Text] [Related]
3. Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces and prevents pain chronification in a mouse model of oxaliplatin-induced neuropathic pain.
Braden K; Stratton HJ; Salvemini D; Khanna R
Neurobiol Pain; 2022; 11():100082. PubMed ID: 35024498
[TBL] [Abstract][Full Text] [Related]
4. Non-SUMOylated CRMP2 decreases Na
Gomez K; Ran D; Madura CL; Moutal A; Khanna R
Mol Brain; 2021 Jan; 14(1):20. PubMed ID: 33478555
[TBL] [Abstract][Full Text] [Related]
5. CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking.
Dustrude ET; Wilson SM; Ju W; Xiao Y; Khanna R
J Biol Chem; 2013 Aug; 288(34):24316-31. PubMed ID: 23836888
[TBL] [Abstract][Full Text] [Related]
6. Studies on CRMP2 SUMOylation-deficient transgenic mice identify sex-specific Nav1.7 regulation in the pathogenesis of chronic neuropathic pain.
Moutal A; Cai S; Yu J; Stratton HJ; Chefdeville A; Gomez K; Ran D; Madura CL; Boinon L; Soto M; Zhou Y; Shan Z; Chew LA; Rodgers KE; Khanna R
Pain; 2020 Nov; 161(11):2629-2651. PubMed ID: 32569093
[TBL] [Abstract][Full Text] [Related]
7. Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels.
François-Moutal L; Scott DD; Perez-Miller S; Gokhale V; Khanna M; Khanna R
Channels (Austin); 2018; 12(1):219-227. PubMed ID: 30081699
[TBL] [Abstract][Full Text] [Related]
8. Targeted transcriptional upregulation of SENP1 by CRISPR activation enhances deSUMOylation pathways to elicit antinociception in the spinal nerve ligation model of neuropathic pain.
Gomez K; Allen HN; Duran P; Loya-Lopez S; Calderon-Rivera A; Moutal A; Tang C; Nelson TS; Perez-Miller S; Khanna R
Pain; 2024 Apr; 165(4):866-883. PubMed ID: 37862053
[TBL] [Abstract][Full Text] [Related]
9. Hierarchical CRMP2 posttranslational modifications control NaV1.7 function.
Dustrude ET; Moutal A; Yang X; Wang Y; Khanna M; Khanna R
Proc Natl Acad Sci U S A; 2016 Dec; 113(52):E8443-E8452. PubMed ID: 27940916
[TBL] [Abstract][Full Text] [Related]
10. TNF-α mediated upregulation of Na
de Macedo FHP; Aires RD; Fonseca EG; Ferreira RCM; Machado DPD; Chen L; Zhang FX; Souza IA; Lemos VS; Romero TRL; Moutal A; Khanna R; Zamponi GW; Cruz JS
Mol Brain; 2019 Dec; 12(1):117. PubMed ID: 31888677
[TBL] [Abstract][Full Text] [Related]
11. A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function.
Dustrude ET; Perez-Miller S; François-Moutal L; Moutal A; Khanna M; Khanna R
Channels (Austin); 2017 Jul; 11(4):316-328. PubMed ID: 28277940
[TBL] [Abstract][Full Text] [Related]
12. Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents.
Cai S; Moutal A; Yu J; Chew LA; Isensee J; Chawla R; Gomez K; Luo S; Zhou Y; Chefdeville A; Madura C; Perez-Miller S; Bellampalli SS; Dorame A; Scott DD; François-Moutal L; Shan Z; Woodward T; Gokhale V; Hohmann AG; Vanderah TW; Patek M; Khanna M; Hucho T; Khanna R
Sci Transl Med; 2021 Nov; 13(619):eabh1314. PubMed ID: 34757807
[TBL] [Abstract][Full Text] [Related]
13. Intranasal CRMP2-Ubc9 inhibitor regulates Na V 1.7 to alleviate trigeminal neuropathic pain.
Loya-Lopez SI; Allen HN; Duran P; Calderon-Rivera A; Gomez K; Kumar U; Shields R; Zeng R; Dwivedi A; Saurabh S; Korczeniewska OA; Khanna R
Pain; 2024 Mar; 165(3):573-588. PubMed ID: 37751532
[TBL] [Abstract][Full Text] [Related]
14. Intranasal CRMP2-Ubc9 Inhibitor Regulates Na
Loya-Lopez SI; Allen HN; Duran P; Calderon-Rivera A; Gomez K; Kumar U; Shields R; Zeng R; Dwivedi A; Saurabh S; Korczeniewska OA; Khanna R
bioRxiv; 2023 Jul; ():. PubMed ID: 37502910
[TBL] [Abstract][Full Text] [Related]
15. Identification and targeting of a unique Na
Gomez K; Stratton HJ; Duran P; Loya S; Tang C; Calderon-Rivera A; François-Moutal L; Khanna M; Madura CL; Luo S; McKiver B; Choi E; Ran D; Boinon L; Perez-Miller S; Damaj MI; Moutal A; Khanna R
Proc Natl Acad Sci U S A; 2023 Aug; 120(32):e2217800120. PubMed ID: 37498871
[TBL] [Abstract][Full Text] [Related]
16. Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats.
Li J; Stratton HJ; Lorca SA; Grace PM; Khanna R
Channels (Austin); 2022 Dec; 16(1):1-8. PubMed ID: 34983286
[TBL] [Abstract][Full Text] [Related]
17. Conditional knockout of CRMP2 in neurons, but not astrocytes, disrupts spinal nociceptive neurotransmission to control the initiation and maintenance of chronic neuropathic pain.
Boinon L; Yu J; Madura CL; Chefdeville A; Feinstein DL; Moutal A; Khanna R
Pain; 2022 Feb; 163(2):e368-e381. PubMed ID: 35029600
[TBL] [Abstract][Full Text] [Related]
18. SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons.
Ju W; Li Q; Wilson SM; Brittain JM; Meroueh L; Khanna R
Channels (Austin); 2013; 7(3):153-9. PubMed ID: 23510938
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated CRMP2 Regulates Spinal Nociceptive Neurotransmission.
Yu J; Moutal A; Dorame A; Bellampalli SS; Chefdeville A; Kanazawa I; Pham NYN; Park KD; Weimer JM; Khanna R
Mol Neurobiol; 2019 Jul; 56(7):5241-5255. PubMed ID: 30565051
[TBL] [Abstract][Full Text] [Related]
20. Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain.
Moutal A; Luo S; Largent-Milnes TM; Vanderah TW; Khanna R
Neurobiol Pain; 2019; 5():. PubMed ID: 31080913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
